Intraoperative Floppy Iris Syndrome Associated with α 1 -Adrenergic Receptor Antagonists

Abstract

OBJECTIVE:

To describe intraoperative floppy iris syndrome (IFIS) in association with α₁-adrenergic receptor (α₁AR) antagonists by conducting a thorough literature review.

DATA SYNTHESIS:

Literature retrieval was accomplished by searching MEDLINE (2000–December 2007) using the terms intraoperative floppy iris syndrome (IFIS), adrenergic α-antagonist(s), tamsulosin, doxazosin, terazosin, and/or alfuzosin. In addition, reference lists from identified publications were reviewed to identify additional reports and studies of interest.

STUDY SELECTION AND DATA EXTRACTION:

All articles in English identified from data sources were reviewed for relevance and uniqueness prior to inclusion.

DATA SYNTHESIS:

IFIS was first described in 2005 as a clinical triad observed during cataract surgery that includes fluttering and billowing of the iris stroma, propensity for iris prolapse, and constriction of the pupil. IFIS increases the risk of complications during cataract surgery. Numerous reports have linked IFIS to use of α₁AR antagonists, most notably tamsulosin, which is prescribed for benign prostatic hyperplasia. Tamsulosin blocks prostatic α_1AARs but may also selectively block α_1AARs in the iris dilator muscle, preventing mydriasis during cataract surgery. Other α₁AR antagonists, including terazosin, doxazosin, and alfuzosin, have also been linked to IFIS; however, their relationship to the syndrome is not as definitive. When ophthalmologists are aware of a patient's previous α₁AR antagonist exposure, specific steps can be taken to reduce the risk of surgical complications. Corrective measures used during surgery have included iris expansion hooks, intracameral phenylephrine, and preoperative atropine.

CONCLUSIONS:

IFIS is a clinical syndrome observed during cataract surgery reported in patients taking systemic α₁AR antagonists. It has been most strongly linked to use of tamsulosin. Medication washout periods of up to 2 weeks and specific surgical procedures have been attempted to reduce risk of complications from α₁AR antagonists in the setting of cataract surgery. Patients should be educated regarding potential risks of this drug class so that they can discuss them with their healthcare providers, specifically ophthalmologists, prior to cataract surgery.